UCLA’s urology department was awarded $6 million from the California Department of Health Care Services to continue providing care and critical services to underinsured and uninsured Californians diagnosed with prostate cancer.
The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company.
